AGING ANALYTICS UK LAUNCHES VITAL, A PREDICTIVE INVESTMENT TOOL FOR THE REGENERATIVE MEDICINE SECTOR

Deep Knowledge Venture Partners Becomes First Fund to Acknowledge Artificial Intelligence, dubbed VITAL, as an Equal Board Member

London, UK (May 13, 2014) – Aging Analytics UK, a new business providing market intelligence on the regenerative medicine sector to pension funds, insurers and governments, today announced the launch of VITAL (Validating Investment Tool for Advancing Life Sciences), an algorithm software focused on a subset of companies in the Regenerative Medical sector.

In conjunction with Aging Analytics, Deep Knowledge Ventures (DKV), a Hong Kong-based venture capital fund focusing on mid-to-long term early-stage biotechnology investments, today announced that it has formally acknowledges VITAL, a crucial Artificial Intelligence instrument for investment decision-making, as an equal member of its Board of Directors.

VITAL uses machine learning to analyze financing trends in a database of life science companies and predict successful investments. It is organized into a framework that describes the nature of their technology, targeted indication or position in the industry ecosystem. Version 1.0 uses basic algorithms focused narrowly on the regenerative medicine sector, making it a unique professional tool for investment exploration.

"We developed VITAL with the goal of creating software that can intuitively predict the success of a project or a company at the initial seed funding level based on an extensive analysis of historical data. Due to lack of public disclosure datasets on investment rounds, intellectual property and clinical trial outcomes are not always available," said senior analyst in Aging Analytics Andrew Garazha. "In spite of this our team of programmers, several of which have theoretical physics backgrounds, are able to use logic to identify probable success based upon an extensive analysis of the parameters involved. Our goal, through iterative releases and updates, is to create a piece of software that is capable of making autonomous investment decisions."

VITAL digs deeper than previous investment tools that have defined the Regenerative Medicine, and analyzes the involvement of companies in the supply chain. It also documents larger companies that are just beginning to explore the sector in early-stage translational trials.

"By breaking down the sector in this way VITAL 1.0 can provide investors with more conservative options for gaining exposure to this high risk/high reward new sector. Our end goal is to develop a program that is capable of making its own investment decisions based upon an investor's preferences," Garazha added.

VITAL can predict the success or failure of any biomedical project as well as the dynamics of success in long-term perspective. The recommendations made by VITAL are strongly logical and free from emotional background, adding a unique skill set to the DKV Board of Directors.

"The prospect for utilizing this approach in portfolio management is very attractive. The variables involved in the long-term success of a biotechnology company are many and complex. We were attracted to a software tool that could in large part automate due diligence and use historical data-sets to uncover trends that are not immediately obvious to human's that are surveying top-line data. We plan to incorporate new information from prospective investments into the databases to compare the outcomes against our selected investment," said DKV Senior Partner Dmitry Kaminskiy.

The regenerative medicine sector encompasses multiple fields of scientific research and clinical applications. While many attempts have been made to compare various companies, research organizations, and research projects, few models account for a company's competitive positioning, growth potential, technology risk or legal risk. Aging Analytics UK will be launching a free Regenerative Medicine Sector Investment Primer on 22nd May 2014 to inform industry stake-holders of the evolving opportunities and associated risks in the sector.

For more information contact:

Jessica Fontaine
Cadogan Consulting Group
+1 561 797 5181
jfontaine@cadoganconsultinggroup.com

About Aging Analytics UK
Aging Analytics UK performs innovative research in biotechnology and regenerative medicine, keeping abreast of the newest processes and technologies for extending life. Through development of databases, frameworks and software supporting financial decision making it provides tools to qualify capital allocation decisions in the public and private sector. The company also provides strategic consulting in the field of regenerative medicine.

About Deep Knowledge Ventures
Deep Knowledge Ventures is a venture capital firm specializing in seed and early stage companies. It seeks to invest in companies and research projects advancing research in age-related diseases, bioinformatics, personalized medicine, and regenerative medicine. Deep Knowledge Ventures is based in Hong Kong. Through our unique partnership with top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution.

With the help of Aging Analytics experts DKV has already closed the first round of investing in two biomedical companies - InSilico Medicine (Baltimore) and Pathway Pharmaceuticals (Hong

Kong). InSilico Medicine was launched on the 6th of March. It focuses on drug-discovery of the geroprotectors and developing new methods of extending life. Pathway Pharmaceuticals, also a promising start-up, focuses exclusively on cancer treatments and personalized medicine in oncological field.